Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

Glutamatergic and dopaminergic modulation of cortico-striatal circuits probed by dynamic calcium imaging of networks reconstructed in microfluidic chips.

Lassus B, Naudé J, Faure P, Guedin D, Von Boxberg Y, Mannoury la Cour C, Millan MJ, Peyrin JM.

Sci Rep. 2018 Nov 29;8(1):17461. doi: 10.1038/s41598-018-35802-9.

2.

Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E, Pastores GM, Rubinsztein DC, Nixon RA, Duchen MR, Mallucci GR, Kroemer G, Levine B, Eskelinen EL, Mochel F, Spedding M, Louis C, Martin OR, Millan MJ.

Nat Rev Drug Discov. 2018 Sep;17(9):660-688. doi: 10.1038/nrd.2018.109. Epub 2018 Aug 17. Review.

PMID:
30116051
3.

Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.

Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, Visca D, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702267. doi: 10.1183/13993003.02267-2017. Print 2018 Mar. No abstract available.

PMID:
29567721
4.

Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine.

Zhang X, Mantas I, Alvarsson A, Yoshitake T, Shariatgorji M, Pereira M, Nilsson A, Kehr J, Andrén PE, Millan MJ, Chergui K, Svenningsson P.

Front Pharmacol. 2018 Mar 1;9:166. doi: 10.3389/fphar.2018.00166. eCollection 2018.

5.

Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling.

Collo G, Cavalleri L, Bono F, Mora C, Fedele S, Invernizzi RW, Gennarelli M, Piovani G, Kunath T, Millan MJ, Merlo Pich E, Spano P.

Neural Plast. 2018 Feb 4;2018:4196961. doi: 10.1155/2018/4196961. eCollection 2018.

6.

Corticotropin-releasing factor receptor 2-deficiency eliminates social behaviour deficits and vulnerability induced by cocaine.

Morisot N, Monier R, Le Moine C, Millan MJ, Contarino A.

Br J Pharmacol. 2018 May;175(9):1504-1518. doi: 10.1111/bph.14159. Epub 2018 Mar 13.

PMID:
29406581
7.

Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3 receptors.

Fasciani I, Pietrantoni I, Rossi M, Mannoury la Cour C, Aloisi G, Marampon F, Scarselli M, Millan MJ, Maggio R.

Eur J Pharmacol. 2018 Jan 15;819:181-189. doi: 10.1016/j.ejphar.2017.12.002. Epub 2017 Dec 6.

PMID:
29223348
8.

Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling.

Cavalleri L, Merlo Pich E, Millan MJ, Chiamulera C, Kunath T, Spano PF, Collo G.

Mol Psychiatry. 2018 Apr;23(4):812-823. doi: 10.1038/mp.2017.241. Epub 2017 Nov 21.

PMID:
29158584
9.

A Molecular Basis for Selective Antagonist Destabilization of Dopamine D3 Receptor Quaternary Organization.

Marsango S, Caltabiano G, Jiménez-Rosés M, Millan MJ, Pediani JD, Ward RJ, Milligan G.

Sci Rep. 2017 May 18;7(1):2134. doi: 10.1038/s41598-017-02249-3.

10.

Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: An integrative review.

Millan MJ.

Prog Neurobiol. 2017 Sep;156:1-68. doi: 10.1016/j.pneurobio.2017.03.004. Epub 2017 Mar 18. Review.

PMID:
28322921
11.

CRF1 but not glucocorticoid receptor antagonists reduce separation-induced distress vocalizations in guinea pig pups and CRF overexpressing mouse pups. A combination study with paroxetine.

Verdouw PM, van Esterik JC, Peeters BW, Millan MJ, Groenink L.

Pharmacol Biochem Behav. 2017 Mar;154:11-19. doi: 10.1016/j.pbb.2017.01.003. Epub 2017 Jan 12.

12.

Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors.

Saavedra OM, Karila D, Brossard D, Rojas A, Dupuis D, Gohier A, Mannoury la Cour C, Millan MJ, Ortuno JC, Hanessian S.

Bioorg Med Chem. 2017 Jan 1;25(1):38-52. doi: 10.1016/j.bmc.2016.10.010. Epub 2016 Oct 12.

PMID:
28029458
13.

Deconstructing vulnerability for psychosis: Meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk.

Fusar-Poli P, Tantardini M, De Simone S, Ramella-Cravaro V, Oliver D, Kingdon J, Kotlicka-Antczak M, Valmaggia L, Lee J, Millan MJ, Galderisi S, Balottin U, Ricca V, McGuire P.

Eur Psychiatry. 2017 Feb;40:65-75. doi: 10.1016/j.eurpsy.2016.09.003. Epub 2016 Dec 16. Review.

14.
15.

Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.

De Deurwaerdère P, Di Giovanni G, Millan MJ.

Prog Neurobiol. 2017 Apr;151:57-100. doi: 10.1016/j.pneurobio.2016.07.002. Epub 2016 Jul 4. Review.

PMID:
27389773
16.

Human Pluripotent Stem Cell-derived Cortical Neurons for High Throughput Medication Screening in Autism: A Proof of Concept Study in SHANK3 Haploinsufficiency Syndrome.

Darville H, Poulet A, Rodet-Amsellem F, Chatrousse L, Pernelle J, Boissart C, Héron D, Nava C, Perrier A, Jarrige M, Cogé F, Millan MJ, Bourgeron T, Peschanski M, Delorme R, Benchoua A.

EBioMedicine. 2016 Jul;9:293-305. doi: 10.1016/j.ebiom.2016.05.032. Epub 2016 May 27.

17.

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.

Bespalov A, Steckler T, Altevogt B, Koustova E, Skolnick P, Deaver D, Millan MJ, Bastlund JF, Doller D, Witkin J, Moser P, O'Donnell P, Ebert U, Geyer MA, Prinssen E, Ballard T, Macleod M.

Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.88. Epub 2016 Jun 17. No abstract available.

PMID:
27312728
18.

Altering the course of schizophrenia: progress and perspectives.

Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, Gallinat J, Giedd J, Grayson DR, Heinrichs M, Kahn R, Krebs MO, Leboyer M, Lewis D, Marin O, Marin P, Meyer-Lindenberg A, McGorry P, McGuire P, Owen MJ, Patterson P, Sawa A, Spedding M, Uhlhaas P, Vaccarino F, Wahlestedt C, Weinberger D.

Nat Rev Drug Discov. 2016 Jul;15(7):485-515. doi: 10.1038/nrd.2016.28. Epub 2016 Mar 4. Review.

PMID:
26939910
19.

Dysbindin-1 modifies signaling and cellular localization of recombinant, human D₃ and D₂ receptors.

Schmieg N, Rocchi C, Romeo S, Maggio R, Millan MJ, Mannoury la Cour C.

J Neurochem. 2016 Mar;136(5):1037-51. doi: 10.1111/jnc.13501. Epub 2016 Jan 21.

20.

Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.

Alvarsson A, Zhang X, Stan TL, Schintu N, Kadkhodaei B, Millan MJ, Perlmann T, Svenningsson P.

J Neurosci. 2015 Oct 14;35(41):14057-69. doi: 10.1523/JNEUROSCI.1312-15.2015.

21.

Lifelong disturbance of serotonin transporter functioning results in fear learning deficits: Reversal by blockade of CRF1 receptors.

Bijlsma EY, Hendriksen H, Baas JM, Millan MJ, Groenink L.

Eur Neuropsychopharmacol. 2015 Oct;25(10):1733-43. doi: 10.1016/j.euroneuro.2015.07.004. Epub 2015 Jul 20.

22.

Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank.

Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, Möller HJ, Dean B.

Int J Neuropsychopharmacol. 2015 Apr 21;18(10):pyv042. doi: 10.1093/ijnp/pyv042. Review.

23.

Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders.

Millan MJ, Goodwin GM, Meyer-Lindenberg A, Ove Ögren S.

Eur Neuropsychopharmacol. 2015 May;25(5):599-656. doi: 10.1016/j.euroneuro.2015.01.016. Epub 2015 Feb 7. Review.

PMID:
25836356
24.

60 years of advances in neuropsychopharmacology for improving brain health, renewed hope for progress.

Millan MJ, Goodwin GM, Meyer-Lindenberg A, Ögren SO.

Eur Neuropsychopharmacol. 2015 May;25(5):591-8. doi: 10.1016/j.euroneuro.2015.01.015. Epub 2015 Feb 7.

PMID:
25799919
25.

Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.

Kamal M, Gbahou F, Guillaume JL, Daulat AM, Benleulmi-Chaachoua A, Luka M, Chen P, Kalbasi Anaraki D, Baroncini M, Mannoury la Cour C, Millan MJ, Prevot V, Delagrange P, Jockers R.

J Biol Chem. 2015 May 1;290(18):11537-46. doi: 10.1074/jbc.M114.559542. Epub 2015 Mar 13.

26.

Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.

Castro-Hernández J, Afonso-Oramas D, Cruz-Muros I, Salas-Hernández J, Barroso-Chinea P, Moratalla R, Millan MJ, González-Hernández T.

Neurobiol Dis. 2015 Feb;74:325-35. doi: 10.1016/j.nbd.2014.12.007. Epub 2014 Dec 12.

PMID:
25511804
27.

Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation.

Maggio R, Scarselli M, Capannolo M, Millan MJ.

Eur Neuropsychopharmacol. 2015 Sep;25(9):1470-9. doi: 10.1016/j.euroneuro.2014.09.016. Epub 2014 Oct 23. Review.

PMID:
25453482
28.

The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?

Millan MJ.

Dialogues Clin Neurosci. 2014 Sep;16(3):373-93. Review.

29.

Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats.

Ingallinesi M, Le Bouil L, Biguet NF, Thi AD, Mannoury la Cour C, Millan MJ, Ravassard P, Mallet J, Meloni R.

Mol Psychiatry. 2015 Aug;20(8):951-8. doi: 10.1038/mp.2014.92. Epub 2014 Aug 26.

PMID:
25155879
30.

Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists.

Hanessian S, Jennequin T, Boyer N, Babonneau V, Soma U, Mannoury la Cour C, Millan MJ, De Nanteuil G.

ACS Med Chem Lett. 2014 Feb 13;5(5):550-5. doi: 10.1021/ml400528y. eCollection 2014 May 8.

31.

Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth.

Duhr F, Déléris P, Raynaud F, Séveno M, Morisset-Lopez S, Mannoury la Cour C, Millan MJ, Bockaert J, Marin P, Chaumont-Dubel S.

Nat Chem Biol. 2014 Jul;10(7):590-7. doi: 10.1038/nchembio.1547. Epub 2014 Jun 1.

PMID:
24880860
32.

Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.

Millan MJ, Fone K, Steckler T, Horan WP.

Eur Neuropsychopharmacol. 2014 May;24(5):645-92. doi: 10.1016/j.euroneuro.2014.03.008. Epub 2014 Apr 4.

33.

CRF₂ receptor-deficiency reduces recognition memory deficits and vulnerability to stress induced by cocaine withdrawal.

Morisot N, Le Moine C, Millan MJ, Contarino A.

Int J Neuropsychopharmacol. 2014 Dec;17(12):1969-79. doi: 10.1017/S1461145714000625. Epub 2014 May 6.

PMID:
24800964
34.

Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E.

Br J Pharmacol. 2014 Aug;171(15):3604-19. doi: 10.1111/bph.12720. Review.

35.

CRF1 receptor-deficiency induces anxiety-like vulnerability to cocaine.

Morisot N, Millan MJ, Contarino A.

Psychopharmacology (Berl). 2014 Oct;231(20):3965-72. doi: 10.1007/s00213-014-3534-1. Epub 2014 Apr 1.

PMID:
24687410
36.

Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists.

Karaki S, Becamel C, Murat S, Mannoury la Cour C, Millan MJ, Prézeau L, Bockaert J, Marin P, Vandermoere F.

Mol Cell Proteomics. 2014 May;13(5):1273-85. doi: 10.1074/mcp.M113.036558. Epub 2014 Mar 17.

37.

Effects of systemically applied nAChRα7 agonists and antagonists on light-induced phase shifts of hamster circadian activity rhythms.

Gannon RL, Garcia DA, Millan MJ.

Eur Neuropsychopharmacol. 2014 Jun;24(6):964-73. doi: 10.1016/j.euroneuro.2013.12.007. Epub 2013 Dec 17.

PMID:
24388152
38.

Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.

Hanessian S, Babonneau V, Boyer N, Mannoury la Cour C, Millan MJ, De Nanteuil G.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):510-4. doi: 10.1016/j.bmcl.2013.12.033. Epub 2013 Dec 15.

PMID:
24374277
39.

Valproate improves prepulse inhibition deficits induced by corticotropin-releasing factor independent of GABA(A) and GABA(B) receptor activation.

Douma TN, Millan MJ, Verdouw PM, Oosting RS, Olivier B, Groenink L.

Neuropharmacology. 2014 Apr;79:66-74. doi: 10.1016/j.neuropharm.2013.10.032. Epub 2013 Nov 7.

PMID:
24211652
40.

CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents.

Douma TN, Millan MJ, Boulay D, Griebel G, Verdouw PM, Westphal KG, Olivier B, Groenink L.

Psychopharmacology (Berl). 2014 Apr;231(7):1289-303. doi: 10.1007/s00213-013-3315-2. Epub 2013 Nov 2.

PMID:
24186076
41.

Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?

Bijlsma EY, Chan JS, Olivier B, Veening JG, Millan MJ, Waldinger MD, Oosting RS.

Pharmacol Biochem Behav. 2014 Jun;121:88-101. doi: 10.1016/j.pbb.2013.10.004. Epub 2013 Oct 12. Review.

PMID:
24128918
42.

Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative.

Millan MJ, Bales KL.

Neurosci Biobehav Rev. 2013 Nov;37(9 Pt B):2166-80. doi: 10.1016/j.neubiorev.2013.09.012. Epub 2013 Sep 30. Review.

PMID:
24090822
43.

Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank.

Dean B, Moller HJ, Svensson TH, Geyer MA, Rujescu D, Scarr E, Millan MJ.

Int J Neuropsychopharmacol. 2014 Jan;17(1):137-48. doi: 10.1017/S1461145713001077. Epub 2013 Sep 24.

PMID:
24063634
44.

On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal.

Millan MJ.

Int J Neuropsychopharmacol. 2014 Jul;17(7):1009-37. doi: 10.1017/S1461145712001496. Epub 2013 May 30. Review.

PMID:
23719026
45.

Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine D3 receptors and Akt-mTORC1 signaling.

Collo G, Bono F, Cavalleri L, Plebani L, Mitola S, Merlo Pich E, Millan MJ, Zoli M, Maskos U, Spano P, Missale C.

Mol Pharmacol. 2013 Jun;83(6):1176-89. doi: 10.1124/mol.113.084863. Epub 2013 Mar 29.

PMID:
23543412
46.

Transient and rapid activation of Akt/GSK-3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens.

Salles MJ, Hervé D, Rivet JM, Longueville S, Millan MJ, Girault JA, Mannoury la Cour C.

J Neurochem. 2013 May;125(4):532-44. doi: 10.1111/jnc.12206. Epub 2013 Mar 11.

47.

An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy.

Millan MJ.

Neuropharmacology. 2013 May;68:2-82. doi: 10.1016/j.neuropharm.2012.11.015. Epub 2012 Dec 11. Review.

PMID:
23246909
48.

5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia.

Meffre J, Chaumont-Dubel S, Mannoury la Cour C, Loiseau F, Watson DJ, Dekeyne A, Séveno M, Rivet JM, Gaven F, Déléris P, Hervé D, Fone KC, Bockaert J, Millan MJ, Marin P.

EMBO Mol Med. 2012 Oct;4(10):1043-56. doi: 10.1002/emmm.201201410.

49.

Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine.

Clifton NE, Morisot N, Girardon S, Millan MJ, Loiseau F.

Psychopharmacology (Berl). 2013 Feb;225(3):579-94. doi: 10.1007/s00213-012-2845-3. Epub 2012 Sep 16.

PMID:
22983144
50.

Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice.

Egeland M, Zhang X, Millan MJ, Mocaer E, Svenningsson P.

J Neurochem. 2012 Dec;123(5):811-23. doi: 10.1111/jnc.12011. Epub 2012 Oct 10.

Supplemental Content

Loading ...
Support Center